ActiveSight to Provide Protein Crystallography to Ambit
News Nov 02, 2005
ActiveSight and Ambit Biosciences have that they have entered into a protein crystallography services agreement to advance Ambit's drug discovery program. The agreement covers the co-crystallization of Ambit proprietary molecules with proteins expressed by ActiveSight.
"We are delighted to provide Ambit, demonstrated leaders in the kinase arena, with structural biology support," stated Ronald V. Swanson, Ph.D., Chief Scientific Officer for ActiveSight.
"I am very pleased that we have initiated this technology collaboration in structural biology with ActiveSight," said Shripad Bhagwat, Sr. Vice President of Drug Discovery at Ambit. "This agreement is intended to accelerate Ambit's kinase drug discovery programs through the application of ActiveSight's protein crystallography technology applied across our discovery portfolio."
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE